Celin Caraballo, NP
Family · Cleveland, OHNPI 1134851520
Payments from drug & device makers
Across 305 payments — averaging $20.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$672
- Lilly USA, LLC$340
- Alkermes, Inc.$315
- Lundbeck LLC$292
- Teva Pharmaceuticals USA, Inc.$264
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,180100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,384 |
| AbbVie | 34 | $672 |
| Lilly USA, LLC | 23 | $340 |
| Alkermes, Inc. | 13 | $315 |
| Lundbeck LLC | 13 | $292 |
| Teva Pharmaceuticals USA, Inc. | 16 | $264 |
| Otsuka America Pharmaceutical, Inc. | 13 | $261 |
| Merck | 11 | $228 |
| Bayer | 6 | $196 |
| Scpharmaceuticals Inc. | 9 | $161 |
| Johnson & Johnson | 8 | $154 |
| Aimmune Therapeutics, Inc. | 9 | $145 |
| Novo Nordisk | 9 | $141 |
| Mylan Specialty L.p. | 6 | $134 |
| GSK | 8 | $124 |
| Averitas Pharma Inc. | 1 | $120 |
| Astellas Pharma US Inc | 7 | $118 |
| UCB, Inc. | 4 | $106 |
| Vanda Pharmaceuticals Inc. | 4 | $106 |
| E.r. Squibb & Sons, L.L.C. | 6 | $93 |
| Amgen(2 entities) | 5 | $83 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $76 |
| Exact Sciences | 4 | $76 |
| Nestle Healthcare Nutrition Inc. | 4 | $68 |
| Xeris Pharmaceuticals, Inc. | 3 | $66 |
| Novartis | 4 | $55 |
| Viatris Specialty LLC | 2 | $48 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Pfizer | 2 | $39 |
| Corcept Therapeutics | 2 | $38 |
| Dexcom, Inc. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Viiv Healthcare Company | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Mannkind Corporation | 1 | $21 |
| Indivior Inc. | 1 | $17 |
| SK Life Science, Inc. | 1 | $17 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,180 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $83,249 |
| MounjaroTirzepatide | 69 | $79,383 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $36,795 |
| JardianceEmpagliflozin | 26 | $33,511 |
| EliquisApixaban | 36 | $33,319 |
| XareltoRivaroxaban | 33 | $32,453 |
| JanuviaSitagliptin Phosphate | 29 | $30,835 |
| TrulicityDulaglutide | 22 | $28,313 |
| FarxigaDapagliflozin Propanediol | 27 | $22,674 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $16,751 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 77 | $11,923 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $7,394 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,595 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $6,447 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $5,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $340 | $107,69691 claims |
| Novo NordiskOzempic | $141 | $83,24961 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $124 | $43,39045 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,384 | $39,42445 claims |
| PfizerEliquis | $39 | $33,31936 claims |
| Johnson & JohnsonXarelto | $154 | $32,45333 claims |
| MerckJanuvia | $228 | $30,83529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Cleveland
- Tina CorkwellCleveland$55K
- Sophia WoodsonCleveland$53K
- Shannon ShafferCleveland$22K
- Christina FerraroCleveland$18K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.